More Ways to Connect
  LinkedIn Twitter YouTube Instagram
Former Olympians Wayne Stetina and Davis Phinney (right) lead the ďpelotonĒ or pack at Sunflower Revolution III.

Former Olympians Wayne Stetina and Davis Phinney (right) lead the ďpelotonĒ or pack at Sunflower Revolution III.

Kim Seroogy, PhD, is studying the relationship between Parkinson's disease and depression.

Michael Behbehani, PhD, and Caryl Sortwell, PhD
Back Next
Publish Date: 12/19/08
Media Contact: Cindy Starr, 513-558-3505
PDF download
RSS feed
related news
share this
Sunflower Revolution Funds Parkinson's Projects

CINCINNATIóScientists at the James J. and Joan A. Gardner Family Center for Parkinsonís Disease and Movement Disorders at the University of Cincinnati Neuroscience Institute have received grants totaling $153,000 for research into Parkinsonís disease.
The funding was provided by the University Hospital Foundation, which co-hosts the annual Sunflower Revolution gala and bike ride with the Colorado-based Davis Phinney Foundation.

Kim Seroogy, PhD, a professor of neurology and director of the Selma Schottenstein Harris Laboratory for Research in Parkinsonís, received $53,000 to study the effects of exercise therapy on stress-induced depression in animal models of Parkinsonís disease.

Seroogy has previously shown that experimental depression exacerbates Parkinsonís symptoms in an animal model of the debilitating movement disorder. Depression is highly correlated with Parkinsonís disease, and exercise is known to produce antidepressant responses in individuals who have depression.

Seroogyís team will attempt to determine the effect of repetitive exercise on coexisting Parkinsonís disease, stress and depression, with the hope that the research will lead to non-pharmocological therapies that will alleviate both mood and motor symptoms of Parkinsonís.

Tim Collier, PhD, a professor of neurology, received $50,000 to investigate the ability of antidepressants to protect dopamine neurons that are lost in the disease in an animal model of Parkinsonís. Although many studies have evaluated the safety and effectiveness of antidepressants in the Parkinsonís disease population, no one has directly investigated whether antidepressants impact the continuing progression of the disease.

About 40-50 percent of Parkinsonís patients are diagnosed with depression and take antidepressants daily. Therefore, it is important to determine whether antidepressants have any effects on the cells that are normally lost in Parkinsonís disease in addition to their ability to relieve the symptoms of depression.

Collier hopes that a better understanding of the impact antidepressants have on the degenerating dopamine system will help clinicians provide better treatment to patients with both depression and Parkinsonís disease.

Caryl Sortwell, PhD, associate professor of neurology, received $50,000 to study the mechanism that may underlie some of the therapeutic benefits of deep brain stimulation in patients with Parkinsonís disease. More than 20,000 patients had received deep brain stimulationóelectrical stimulation of the subthalamic nucleus via implanted electrodesóas of 2006.

Sortwell and her co-investigators will use an existing rodent model of Parkinsonís to study the effects of acute and chronic deep brain stimulation on the neurotransmitter glutamate. In a previous study funded by the Davis Phinney Foundation and the University Hospital Foundation, Sortwell found that the act of stimulating neurons with electrodes boosted the amount of a nurturing, growth-promoting protein in the ratsí brains.

In her new study, Sortwell will incorporate state-of-the-art technology to detect low levels of glutamate in the substantia nigra, an area of the brain that receives inervation from the subthalamic nucleus and that contains dopamine neurons. Sortwell also will use the study to document the extent to which deep brain stimulation protects healthy dopamine neurons in the rodentsí brains.

The UC Neuroscience Institute, a regional center of excellence at UC and University Hospital, is dedicated to patient care, research, education, and the development of new treatments for stroke, brain and spinal tumors, epilepsy, traumatic brain and spinal injury, multiple sclerosis, Parkinsonís disease, Alzheimerís disease, disorders of the nerves and muscles, disorders of the senses (swallowing, voice, hearing, pain, taste, and smell) and psychiatric conditions (bipolar disorder, schizophrenia and depression).

 back to list | back to top